2026-06-14T02:29:51Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/199992024-11-29T07:23:31Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Price, David author Fromer, Leonard author Kaplan, Alan author van der Molen, Thys author Roman-Rodriguez, Miguel 2024-07-03T11:09:21Z 2024-07-03T11:09:21Z 2014-07-17 Price D, Fromer L, Kaplan A, Van Der Molen T, Román-Rodríguez M. Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?. NPJ Prim Care Respir Med. 2014 Jul 17;24:14023. 10.1038/npjpcrm.2014.23 2055-1010 NPJ Primary Care Respiratory Medicine http://hdl.handle.net/20.500.13003/17471 25030457 L373550814 2-s2.0-84904402865 http://hdl.handle.net/20.500.12105/19999 345386400001 Despite current guidelines and the range of available treatments, over a half of patients with asthma continue to suffer from poor symptomatic control and remain at risk of future worsening. Although a number of non-pharmacological measures are crucial for good clinical management of asthma, new therapeutic controller medications will have a role in the future management of the disease. Several long-acting anticholinergic bronchodilators are under investigation or are available for the treatment of respiratory diseases, including tiotropium bromide, aclidinium bromide, glycopyrronium bromide, glycopyrrolate and umeclidinium bromide, although none is yet licensed for the treatment of asthma. A recent Phase III investigation demonstrated that the once-daily long-acting anticholinergic bronchodilator tiotropium bromide improves lung function and reduces the risk of exacerbation in patients with symptomatic asthma, despite the use of inhaled corticosteroids (ICS) and long-acting beta(2)-agonists (LABAs). This has prompted the question of what the rationale is for long-acting anticholinergic bronchodilators in asthma. Bronchial smooth muscle contraction is the primary cause of reversible airway narrowing in asthma, and the baseline level of contraction is predominantly set by the level of 'cholinergic tone'. Patients with asthma have increased bronchial smooth muscle tone and mucus hypersecretion, possibly as a result of elevated cholinergic activity, which anticholinergic compounds are known to reduce. Further, anticholinergic compounds may also have anti-inflammatory properties. Thus, evidence suggests that long-acting anticholinergic bronchodilators might offer benefits for the maintenance of asthma control, such as in patients failing to gain control on ICS and a LABA, or those with frequent exacerbations. eng Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma? review article